AMENDING AGREEMENT #1
Exhibit 10.30.2
|
|
*** TEXT OMITTED AND SUBMITTED SEPARATELY PURSUANT TO CONFIDENTIAL TREATMENT REQUEST UNDER 17 C.F.R. SECTIONS 200.80(b)(4) AND 230.406 |
REF : C2007-034
THIS AMENDING AGREEMENT is effective as of May 26, 2008 (hereinafter referred to as “Effective Date”) and is made:
|
BETWEEN: |
|
HÉMA-QUÉBEC |
|
|
|
0000 Xxxx-Xxxxx Xxxx. |
|
|
|
Xxxxx-Xxxxxxx (Xxxxxx) X0X 0X0 |
|
|
|
XXXXXX |
|
|
|
|
|
|
|
(hereinafter referred to as “HQ”) |
|
|
|
|
|
AND: |
|
|
|
|
|
|
|
|
|
TALECRIS BIOTHERAPEUTICS LTD. |
|
|
|
0000 Xxxxxxxx Xxxxx, Xxxxx 000 |
|
|
|
Xxxxxxxxxxx (Xxxxxxx) X0X 0X0 |
|
|
|
XXXXXX |
|
|
|
|
|
|
|
(hereinafter referred to as “TALECRIS CANADA”) |
|
|
|
|
|
AND: |
|
|
|
|
|
TALECRIS BIOTHERAPEUTICS INC. |
|
|
|
X.X. Xxx 00000 |
|
|
|
79 XX Xxxxxxxxx Xxxxx |
|
|
|
Xxxxxxxx Xxxxxxxx Xxxx (Xxxxx Xxxxxxxx) 00000 |
|
|
|
XXX |
|
|
|
|
|
|
|
(hereinafter referred to as “TALECRIS US”) |
|
|
|
|
|
|
|
(TALECRIS US and TALECRIS CANADA are hereinafter collectively referred to as the “Supplier”) |
WHEREAS the Parties entered into a Purchase Agreement for Fractionation Services and Commercial Products made as of the lst day of April, 2008 (the “Purchase Agreement”);
WHEREAS the Parties desire to amend the Purchase Agreement in order to modify the Testing Services fee and the price per unit of measure for GamaSTANMC S/D.
NOW, THEREFORE, in consideration of the mutual covenants and premises contained in this Amending Agreement, the Parties agree as follows:
1. The revised fee for B19 Testing Services shall be [***] $US per sample commencing April 1, 2008.
*** CONFIDENTIAL TREATMENT REQUESTED
REF: C2007-034
2. The revised price for GamaSTANMC S/D shall be [***] $US per mL commencing April 1, 2008.
Except as noted above, aall other covenants, terms, and conditions contained in the Purchase Agreement shall remained unchanged.
IN WITNESS WHEREOF the Parties have caused this Amending Agreement to be executed by their duly authorized officers, as of the date first written above.
|
HÉMA-QUÉBEC |
TALECRIS BIOTHERAPEUTICS INC. |
|||
|
|
|
|||
|
|
|
|
||
|
BY: |
/s/ Xxxxxxxx Xxxxxx |
|
BY: |
/s/ Xxxx Xxxxxxx |
|
|
|
|
|
|
|
NAME: |
Xxxxxxxx Xxxxxx |
|
NAME: |
Xxxx Xxxxxxx |
|
|
(printed) |
|
|
(printed) |
|
|
|
|
|
|
|
TITLE: |
President and Chief Executive Officer |
|
TITLE: |
Senior Vice-President and General Manager |
|
|
|
|
|
|
|
DATE: |
June 20, 2008 |
|
DATE: |
June 11, 2008 |
|
|
|
|
||
|
TALECRIS BIOTHERAPEUTICS LTD. |
|
|
||
|
|
|
|
||
|
|
|
|
||
|
BY: |
/s/ Xxxx Xxxxxxx |
|
|
[SEAL] |
|
|
|
|
|
|
|
NAME: |
Xxxx Xxxxxxx |
|
|
|
|
|
(printed) |
|
|
|
|
|
|
|
|
|
|
TITLE: |
Senior Vice-President and General Manager |
|
|
|
|
|
|
|
|
|
|
DATE: |
June 11, 2008 |
|
|
|
*** CONFIDENTIAL TREATMENT REQUESTED
